Engraftment Kinetics of Peripheral Blood Stem Cells

Title:  UARK 2008-22, Engraftment Kinetics of Peripheral Blood Stem Cells (PBSCs) Isolated Using the Spectra Optia Apheresis System Protocol #: BCT07-30 
Sponsor:  CaridianBCT, Inc. 
PI:  Michele Fox, MD 
Phase:  III 
Purpose:  This study is being done to determine if stem cells harvested by an experimental apheresis device, the Spectra Optia, rescue damaged bone marrow (engraft) as well as stem cells harvested by similar devices that are already approved for this use.

The Spectra Optia is being developed by CaridianBCT, Inc. to harvest hematopoetic stem cells from peripheral blood. It is hoped that the Spectra Optia will provide a more efficient and easier-to-use apheresis device. 

Eligibility:  This study will include patients who have either received a stem cell transplant and/or who have developed cancer of the blood or bone marrow.

To be included in the study, your doctor must have a high suspicion that you have invasive infection with Aspergillus. The diagnosis can be pending at the time that you enter the study. Your doctor will perform testing during the study to confirm whether you have or do not have infection with Aspergillus.

Up to 10 research subjects, male or female, age 18 and older, regardless of race or ethnicity, will take part in this study at the Myeloma Institute for Research & Therapy (MIRT). 

Treatment:  You and your doctor have decided to treat your multiple myeloma with high-dose chemotherapy and bone marrow rescue. The bone marrow rescue is necessary because the high-dose chemotherapy intended to kill your multiple myeloma also damages your bone marrow. The bone marrow rescue is accomplished by harvesting peripheral blood stem cells from you, before chemotherapy, and then returning the same cells to you after chemotherapy.

Participation in the study will last approximately 20 weeks and includes a 3-month follow-up period. 

Contact:  Nathan Petty
E-mail: pettynathanm@uams.edu
Phone: 501-526-6990 ext. 2435